Disc Medicine Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target
Buy Rating Affirmed: Strong Phase 2 Results and Strategic FDA Engagement Bolster Confidence in Disc Medicine's Pipeline
BMO Capital Reiterates Outperform on Disc Medicine, Raises Price Target to $70
Wedbush Raises Disc Medicine Price Target to $57 From $43, Maintains Outperform Rating
HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target
Disc Medicine Analyst Ratings
Disc Medicine Analyst Ratings
Disc Medicine Analyst Ratings
Cantor Fitzgerald Company: Reiterates Disc Medicine (IRON.US) rating and adjusted from increased holdings to increased holdings, with a target price of $85.00.
Cantor Fitzgerald Keeps Their Buy Rating on Disc Medicine (IRON)
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Disc Medicine Analyst Ratings
Raymond James: Maintaining the Disc Medicine (IRON.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $40.00 to $43.00.
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Electrocore (ECOR), Disc Medicine (IRON) and Allakos (ALLK)
Optimistic Buy Rating for Disc Medicine Amid Anticipated Study Results and Strong Financial Position
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), Disc Medicine (IRON) and Avita Medical (RCEL)
Stifel: Maintaining the Disc Medicine (IRON.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $71.00 to $73.00.
Disc Medicine Analyst Ratings